Van Berkom & Associates Inc. Has $1.45 Million Holdings in Bio-Techne Co. (NASDAQ:TECH)

Van Berkom & Associates Inc. lessened its holdings in Bio-Techne Co. (NASDAQ:TECH) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,132 shares of the biotechnology company’s stock after selling 652 shares during the quarter. Van Berkom & Associates Inc.’s holdings in Bio-Techne were worth $1,450,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Bio-Techne by 46.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,650 shares of the biotechnology company’s stock valued at $1,215,000 after acquiring an additional 5,295 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Bio-Techne by 58.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 43,298 shares of the biotechnology company’s stock valued at $3,119,000 after purchasing an additional 16,038 shares during the period. Oddo BHF Asset Management Sas bought a new position in shares of Bio-Techne in the 3rd quarter worth $1,188,000. Quest Partners LLC acquired a new stake in shares of Bio-Techne during the third quarter worth $43,000. Finally, Broadcrest Asset Management LLC increased its holdings in Bio-Techne by 100.0% in the third quarter. Broadcrest Asset Management LLC now owns 200,000 shares of the biotechnology company’s stock valued at $15,986,000 after purchasing an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Bio-Techne Stock Performance

Shares of TECH opened at $65.49 on Friday. The firm has a market cap of $10.35 billion, a P/E ratio of 66.15, a PEG ratio of 2.89 and a beta of 1.27. Bio-Techne Co. has a twelve month low of $61.16 and a twelve month high of $85.57. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.77 and a current ratio of 3.94. The firm’s 50 day moving average price is $72.91 and its two-hundred day moving average price is $73.52.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. On average, analysts forecast that Bio-Techne Co. will post 1.67 EPS for the current fiscal year.

Bio-Techne Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Investors of record on Monday, February 17th will be given a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date of this dividend is Friday, February 14th. Bio-Techne’s dividend payout ratio is presently 32.32%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on TECH shares. Robert W. Baird cut Bio-Techne from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $88.00 to $68.00 in a report on Wednesday. KeyCorp increased their price target on shares of Bio-Techne from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Royal Bank of Canada boosted their price objective on shares of Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a report on Thursday, February 6th. Baird R W lowered shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, Scotiabank lifted their price target on shares of Bio-Techne from $88.00 to $90.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 6th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $84.29.

Insider Buying and Selling at Bio-Techne

In other Bio-Techne news, Director Amy E. Herr sold 1,860 shares of Bio-Techne stock in a transaction on Friday, February 14th. The shares were sold at an average price of $65.96, for a total value of $122,685.60. Following the sale, the director now directly owns 1,976 shares in the company, valued at approximately $130,336.96. The trade was a 48.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kim Kelderman sold 13,392 shares of the business’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the sale, the chief executive officer now directly owns 39,004 shares in the company, valued at $3,014,619.16. This trade represents a 25.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.